⚠ Evidence warning: Clinical trials or other evidence do not support the claims that valerian-lemon balm combinations work better than either herb alone and that they help people taper off prescription sleeping pills. This page keeps it as a report of what people, websites or other media say.

Lemon Balm for Sleep Quality

Lemon balm is most commonly used not as a primary sedative but as the calming partner in valerian-lemon balm combinations — valerian provides the sleep-onset push, lemon balm prevents the next-day grogginess and adds a layer of mucosal calming through its GABAergic effect. The two most-cited studies are the Cases 2011 open-label trial of a standardized lemon balm extract (600 mg/day) in 20 volunteers with mild-to-moderate anxiety and concurrent sleep disturbance, and the Müller and Klement 2006 open multicentre study of a valerian-plus-lemon-balm combination in 918 children under 12 with restlessness and dyssomnia. Neither had a placebo group; both reported improvements in sleep symptoms and no study-medication-related adverse effects, and a small 2024 placebo-controlled crossover trial reported better sleep scores with a lemon balm extract. This page walks through the mechanism (shared GABAergic action with valerian, plus contributions from citral and rosmarinic acid), the doses used in trials and in herbal practice for daytime and evening use, and how lemon balm-containing sleep products compare with plain valerian, melatonin and prescription Z-drugs.


Table of Contents

  1. Why Lemon Balm Matters for Sleep
  2. The Cases 2011 Lemon Balm Extract Trial
  3. A Placebo-Controlled Crossover Trial in 2024
  4. The Müller-Klement 2006 Pediatric Trial
  5. The Shared GABAergic Mechanism
  6. Dose Timing: Daytime Anxiolytic vs Evening Sleep Onset
  7. Lemon Balm Plus Valerian Combinations
  8. Lemon Balm Plus Chamomile and Passionflower
  9. Lemon Balm vs Melatonin
  10. Lemon Balm vs Zolpidem and the Z-Drugs
  11. Sleep Protocols Described by Phenotype
  12. Cautions and Drug Interactions
  13. Key Research Papers
  14. Connections
  15. Featured Videos

Why Lemon Balm Matters for Sleep

Insomnia is conventionally divided into three phenotypes: difficulty falling asleep (sleep-onset insomnia), difficulty staying asleep (sleep-maintenance insomnia), and early-morning awakening with inability to return to sleep. These phenotypes have different physiology and respond to different interventions. The largest of the three by population prevalence — sleep-onset insomnia, particularly in patients whose racing thoughts and physiological hyperarousal prevent the transition from wakefulness to sleep — is the type best served by lemon balm.

The physiological transition from awake to asleep requires a coordinated drop in sympathetic nervous system tone, a rise in parasympathetic activation, and an inhibitory shift in the prefrontal cortex that allows the default mode network and rumination circuits to quiet. Stress-driven insomnia is characterized by failure of this transition — sympathetic tone remains elevated, the prefrontal cortex stays engaged in problem-solving and worry, and the resulting hyperaroused state is incompatible with sleep onset.

Pharmacologic strategies for stress-driven sleep-onset insomnia divide into three broad categories:

  1. Direct gamma-aminobutyric acid-A agonists or modulators — benzodiazepines (lorazepam, temazepam), Z-drugs (zolpidem, eszopiclone, zaleplon). Highly effective for sleep onset but with dependence, tolerance, next-day cognitive impairment, and complex sleep behaviors
  2. Indirect GABAergic agents — valerian, lemon balm, kava, hops. Modulate GABAergic tone through diverse mechanisms (gamma-aminobutyric acid-T inhibition, allosteric receptor modulation, increased gamma-aminobutyric acid (GABA) release) with much milder effect but excellent safety
  3. Circadian agents — melatonin, ramelteon, agomelatine. Target the circadian phase rather than the gamma-aminobutyric acid system; most useful for circadian-rhythm sleep disturbance rather than primary insomnia

Lemon balm sits in the indirect GABAergic category, complementing rather than replacing valerian. Its sleep-supportive effect is real but modest in isolation; combined with valerian it is part of one of the best-studied non-prescription sleep formulations in European phytotherapy.

The anxiety side of that effect has been pooled across trials. A 2021 systematic review and meta-analysis of randomized trials (Ghazizadeh and colleagues) found that lemon balm improved anxiety scores (standardized mean difference −0.98) and depression scores (−0.47) compared with placebo, without serious side effects. The authors note that the trials were few, differed in method and gave widely varying results (high heterogeneity), so the findings are to be read with caution.

Back to Table of Contents

The Cases 2011 Lemon Balm Extract Trial

The most-cited lemon-balm-monotherapy sleep trial was published by Jonathan Cases and colleagues in 2011 (Mediterranean Journal of Nutrition and Metabolism). The study was a prospective, single-center, open-label pilot trial in 20 stressed volunteers (outpatients; 14 women and 6 men aged 18 to 70) with mild-to-moderate anxiety disorders and sleep disturbances, recruited through advertisements and from the outpatient Dietetics and Clinical Nutrition Unit of San Martino University Hospital in Genoa, Italy. The intervention was a standardized hydroalcoholic Melissa officinalis leaf extract, standardized to more than 7% rosmarinic acid and more than 15% hydroxycinnamic acid derivatives, given as 300 mg in the morning and 300 mg in the evening before sleep (600 mg/day) for 15 days. Four of the five authors worked for the extract's manufacturer, which also gave the study financial assistance.

Outcome measures at baseline and day 15 included:

After 15 days of treatment, the trial reported:

The trial has the standard limitations of an open-label pilot — no placebo control, small sample size, single proprietary extract, short duration — and the authors themselves write that the open-label design cannot rule out a placebo effect and that future studies must include a placebo arm.

Back to Table of Contents

A Placebo-Controlled Crossover Trial in 2024

A 2024 double-blind, placebo-controlled crossover study in Italy (Di Pierro and colleagues, Nutrients) tested a lemon balm extract bound to phospholipids (a “phytosome” form made to be absorbed better). Thirty adults took two 200 mg tablets of the extract or of a placebo every evening 30 minutes before bed for two weeks each, with a one-week break between the two periods. The study reported:

The study was small and short, and its first author is scientific director of the company that sells the extract, with two other authors consultants to it.

Back to Table of Contents

The Müller-Klement 2006 Pediatric Trial

The largest study of a lemon-balm-containing sleep formulation in children was the open, uncontrolled multicentre study published by Sabine F. Müller and Susanna Klement in 2006 (Phytomedicine). It evaluated 918 children under 12 years of age with restlessness and nervous sleep difficulty ("dyssomnia"). The intervention was a fixed-dose combination product of 160 mg valerian extract plus 80 mg lemon balm extract per tablet, and the investigators dosed each child individually. The first author worked for the company that makes the product.

Parents and investigators scored:

Results:

This study remains the principal evidence cited for valerian-lemon balm combination products for restlessness and sleep difficulty in children in European phytotherapy practice. It had no placebo or comparison group, which limits causal interpretation; its main contribution is tolerability data in a large group of children.

Back to Table of Contents

The Shared GABAergic Mechanism

The synergy between valerian and lemon balm in sleep formulations is mechanistically rational because both herbs act on the GABAergic system but at different points:

The combined effect is increased synaptic gamma-aminobutyric acid from two complementary mechanisms (reduced reuptake plus reduced catabolism), acting on a gamma-aminobutyric acid-A receptor whose response is enhanced by valerenic acid's allosteric modulation. This multi-point GABAergic stack is the proposed reason the combination would give a stronger and more reliable sleep-supportive effect than either herb alone.

The advantage of indirect GABAergic potentiation over direct benzodiazepine-style receptor agonism is selectivity. Benzodiazepines act on every gamma-aminobutyric acid-A receptor in the brain at once, producing sleep but also amnesia, ataxia, and the muscle relaxation that contributes to falls. Indirect potentiation through gamma-aminobutyric acid-T inhibition or reuptake inhibition raises GABAergic tone preferentially in synapses that were already firing, which preserves more of the physiological pattern of sleep and produces less of the global central nervous system (CNS) suppression that causes benzodiazepine side effects.

This is the pharmacological reason that valerian-lemon balm combinations rarely cause next-day grogginess at typical doses, while equivalent benzodiazepine doses commonly do.

Back to Table of Contents

Dose Timing: Daytime Anxiolytic vs Evening Sleep Onset

The same lemon balm extract is used as a daytime anxiolytic or as an evening sleep-onset aid, with different timing. The doses below are those used in the trials on this page or described in herbal practice:

Onset of sleep-supportive effect from oral lemon balm is described as typically 45-90 minutes (somewhat slower than benzodiazepines or Z-drugs, which act within 15-30 minutes). For people used to fast-acting sleeping pills, the slower onset can feel like ineffectiveness; the herb is described as needing more lead time and as more useful for "winding down" before sleep than for fast sleep onset.

Back to Table of Contents

Lemon Balm Plus Valerian Combinations

The valerian-plus-lemon-balm combination is the canonical European phytotherapy sleep formulation. The product used in the Müller-Klement 2006 study provides 160 mg valerian extract and 80 mg lemon balm extract per tablet. The fixed-dose ratio reflects the relative anxiolytic and sleep-onset contributions of each herb — valerian carries most of the sleep-onset signal, lemon balm contributes the calming anxiolytic background.

Trial evidence for the combination specifically:

In European phytotherapy practice the valerian-lemon balm combination is used as a non-prescription option for sleep-onset difficulty with anxiety. The regimen usually described is 1-2 tablets of a 160 mg valerian + 80 mg lemon balm fixed-dose product, 30-60 minutes before bed. Practitioners describe the effect as more reliable after 2-3 weeks of nightly use than from a single dose, with as-needed use also common.

Valerian itself, the main partner in these combinations, has weak trial support on its own. A 2007 systematic review of 37 studies (Taibi and colleagues, titled “A systematic review of valerian as a sleep aid: safe but not effective”) found that most controlled studies showed no significant difference between valerian and placebo, in healthy people or in people with insomnia; none of the most recent and most rigorous studies found a significant effect on sleep; and adverse events were rare.

See Valerian for the full valerian profile.

Back to Table of Contents

Lemon Balm Plus Chamomile and Passionflower

A broader European phytotherapy tradition combines lemon balm with chamomile, passionflower, and sometimes hops in multi-herb anxiolytic-sleep blends. The pharmacology rationale is the same multi-target GABAergic potentiation discussed above, with chamomile's apigenin contributing benzodiazepine-binding-site partial agonism, passionflower's flavonoids contributing additional gamma-aminobutyric acid-A modulation, and hops contributing methylbutenol-derived sedation.

Trial evidence for these broader combinations is sparser than for the valerian-lemon balm pairing, but the tradition is long-established and the combinations are well-tolerated. Common formats include:

The practical advantage of multi-herb formulations is broader-spectrum coverage of different sleep phenotypes — sleep-onset (valerian, hops), middle-of-the-night awakening (passionflower), sleep-maintenance (chamomile), and the underlying daytime anxiety that drives chronic insomnia (lemon balm). The disadvantage is reduced dose precision per ingredient and harder reproducibility.

See Chamomile and Passionflower.

Back to Table of Contents

Lemon Balm vs Melatonin

Melatonin is the most-used over-the-counter sleep aid in the United States, with annual sales exceeding 500 million USD. Mechanistically, melatonin is fundamentally different from lemon balm — it is the endogenous circadian signal of darkness, working through MT1 and MT2 receptors in the suprachiasmatic nucleus to advance or delay circadian phase, rather than through any GABAergic mechanism. Its primary value is for circadian-rhythm sleep disturbance (jet lag, shift work, delayed sleep-phase syndrome) rather than primary insomnia.

Compared to melatonin, lemon balm has:

Melatonin's research base lies mainly in circadian phase problems (jet lag east-bound, shift work, delayed sleep-phase syndrome); lemon balm and valerian-lemon balm combinations are used mainly for stress-driven sleep onset difficulty with anxiety. Some people use both, taken at different times for different reasons.

Back to Table of Contents

Lemon Balm vs Zolpidem and the Z-Drugs

The Z-drugs — zolpidem, eszopiclone, zaleplon — are the most-prescribed sleep medications in the United States. They are non-benzodiazepine gamma-aminobutyric acid-A agonists that selectively bind the alpha-1 subunit of the gamma-aminobutyric acid-A receptor, producing sleep onset within 15-30 minutes. They are effective for short-term insomnia management but carry well-documented risks: complex sleep behaviors (sleep-driving, sleep-eating, sleep-walking), anterograde amnesia, falls in elderly patients, dependence, and rebound insomnia on discontinuation.

Lemon balm-containing sleep formulations cannot match Z-drugs on speed of sleep onset or absolute efficacy in severe insomnia. They can, however, offer:

The current U.S. Food and Drug Administration (FDA)-approved labels describe zolpidem and zaleplon for the short-term treatment of insomnia: zolpidem shortened the time to fall asleep for up to 35 days in controlled studies (trials of 4 to 5 weeks), and zaleplon for up to 30 days. The eszopiclone label lists the treatment of insomnia, with supporting trials of up to 6 months. All three labels carry a boxed warning about complex sleep behaviors and warn that withdrawal symptoms may occur with rapid dose reduction or stopping. In herbal practice, lemon balm-containing combinations are used for chronic mild-to-moderate sleep difficulty, by people who want to avoid prescription dependence, in older adults, in whom Z-drugs carry particular risks of falls and confusion, and during tapering off chronic Z-drug or benzodiazepine use.

Back to Table of Contents

Sleep Protocols Described by Phenotype

The trials above and herbal practice describe different approaches for different sleep problems:

Back to Table of Contents

Cautions and Drug Interactions

Back to Table of Contents

Key Research Papers

  1. Cases J, Ibarra A, Feuillère N, Roller M, Sukkar SG (2011). Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Mediterranean Journal of Nutrition and Metabolism 2011;4(3):211-218. — PubMed PMID: 22207903
  2. Müller SF, Klement S (2006). A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. Phytomedicine 2006;13(6):383-387. — PubMed PMID: 16487692
  3. Di Pierro F, Sisti D, Rocchi M, Belli A, Bertuccioli A, Cazzaniga M, Palazzi CM, Tanda ML, Zerbinati N (2024). Effects of Melissa officinalis Phytosome on Sleep Quality: Results of a Prospective, Double-Blind, Placebo-Controlled, and Cross-Over Study. Nutrients 2024;16(23):4199. — PubMed PMID: 39683592
  4. Ghazizadeh J, Sadigh-Eteghad S, Marx W, Fakhari A, Hamedeyazdan S, Torbati M, Taheri-Tarighi S, Araj-Khodaei M, Mirghafourvand M (2021). The effects of lemon balm (Melissa officinalis L.) on depression and anxiety in clinical trials: A systematic review and meta-analysis. Phytotherapy Research 2021;35(12):6690-6705. — PubMed PMID: 34449930
  5. Cerny A, Schmid K (1999). Tolerability and efficacy of valerian/lemon balm in healthy volunteers (a double-blind, placebo-controlled, multicentre study). Fitoterapia 1999;70(3):221-228. — doi:10.1016/S0367-326X(99)00018-0
  6. Schulz V, Hänsel R, Tyler VE (2001). Central Nervous System. In: Rational Phytotherapy: A Physicians' Guide to Herbal Medicine. Springer, Berlin, Heidelberg. — doi:10.1007/978-3-642-98093-0_2
  7. Kennedy DO, Little W, Haskell CF, Scholey AB (2006). Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress. Phytotherapy Research 2006;20(2):96-102. — PubMed PMID: 16444660
  8. Awad R, Levac D, Cybulska P, Merali Z, Trudeau VL, Arnason JT (2007). Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Canadian Journal of Physiology and Pharmacology 2007;85(9):933-942. — PubMed PMID: 18066140
  9. Khom S, Baburin I, Timin E, Hohaus A, Trauner G, Kopp B, Hering S (2007). Valerenic acid potentiates and inhibits GABA-A receptors: molecular mechanism and subunit specificity. Neuropharmacology 2007;53(1):178-187. — PubMed PMID: 17585957
  10. Bent S, Padula A, Moore D, Patterson M, Mehling W (2006). Valerian for sleep: a systematic review and meta-analysis. American Journal of Medicine 2006;119(12):1005-1012. — PubMed PMID: 17145239
  11. Taibi DM, Landis CA, Petry H, Vitiello MV (2007). A systematic review of valerian as a sleep aid: safe but not effective. Sleep Medicine Reviews 2007;11(3):209-230. — PubMed PMID: 17517355
  12. Wheatley D (2005). Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. Journal of Psychopharmacology 2005;19(4):414-421. — PubMed PMID: 15982998
  13. Sarris J, Byrne GJ (2011). A systematic review of insomnia and complementary medicine. Sleep Medicine Reviews 2011;15(2):99-106. — PubMed PMID: 20965131
  14. Shakeri A, Sahebkar A, Javadi B (2016). Melissa officinalis L. - A review of its traditional uses, phytochemistry and pharmacology. Journal of Ethnopharmacology 2016;188:204-228. — PubMed PMID: 27167460
  15. Erland LA, Saxena PK (2017). Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content. Journal of Clinical Sleep Medicine 2017;13(2):275-281. — PubMed PMID: 27855744

PubMed Topic Searches

  1. PubMed: Melissa officinalis sleep
  2. PubMed: Valerian-lemon balm combination
  3. PubMed: Standardized lemon balm extract sleep trials
  4. PubMed: Pediatric valerian-lemon balm
  5. PubMed: Herbal anxiolytic insomnia review
  6. PubMed: Valerenic acid GABA

Back to Table of Contents

Connections

Back to Table of Contents